YOLFTbeta
77

AnnJi Pharmaceutical Co., Ltd.

7754 · TWO · Healthcare / Biotechnology

65.00TWD-0.20 (-0.31%)

Price History

Full chart

Market Stats

Previous Close65.20
Open65.20
Day Range64.30 – 66.60
52-Week Range44.00 – 78.50
Volume240.76K
Market Cap7.89B
P/E (TTM)0.00
Forward P/E0.00
EPS-4.20
Dividend Yield0.00%
Beta-0.30
50-Day Avg60.34
200-Day Avg58.38

About

AnnJi Pharmaceutical Co., Ltd. develops drugs in the therapeutic areas of neurology, dermatology, and inflammatory disorders. It develops therapeutics, such as AJ201 for the treatment of spinal and bulbar muscular atrophy; AJ302, a histone deacetylase 6 inhibitor for the prevention and treatment of chemotherapy-induced peripheral neuropathy; and AJ303, an anti-fibrotic and anti-inflammatory compound for the treatment of idiopathic pulmonary fibrosis. AnnJi Pharmaceutical Co., Ltd. was founded in 2014 and is based in Taipei, Taiwan.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Wenying Huang Ph.D.
  • Headquarters16F.-6, No. 508, Sec. 7, Taipei, Taiwan, 115011, Taiwan
  • Websitehttps://www.ajpharm.com

Leadership

  • Dr. Wenying Huang Ph.D.Chairman & CEO
  • Mr. Lewis YehChief Financial Officer
  • Junyan YeAccounting Supervisor
  • Dr. Dennis Huang M.D.Head of Clinical Research & Medical Affairs

Financials

Income Statement

Currency: TWD2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue1.44M1.63M143.53M96.45M7.55M
Growth (%)-+13.31%+8727.18%-32.80%-92.17%
Cost of Revenue459.00K511.00K125.09M87.56M6.29M
Gross Profit976.00K1.11M18.44M8.89M1.26M
Gross Margin68.01%68.57%12.85%9.22%16.64%
Operating Expense203.25M241.61M287.06M369.03M370.63M
Operating Income-202.28M-240.50M-268.62M-360.14M-369.37M
Operating Margin-14095.82%-14790.59%-187.15%-373.40%-4891.01%
EBITDA-156.86M-194.60M-252.01M-322.53M-311.11M
EBITDA Margin-10931.22%-11968.08%-175.58%-334.41%-4119.53%
Net Income-198.63M-236.65M-329.22M-353.99M-357.87M
Net Income Margin-13841.46%-14554.12%-229.37%-367.02%-4738.73%
R&D184.42M223.43M247.15M321.49M339.86M
R&D as % of Total Revenue12851.57%13741.02%172.19%333.33%4500.23%
Interest Expense150.00K32.00K471.00K1.78M1.60M
Interest Expense % of Total Revenue10.45%1.97%0.33%1.85%21.20%

Balance Sheet

Currency: TWD2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets666.54M541.23M1.21B1.00B590.11M
Total Liabilities16.41M30.72M282.94M339.90M270.29M
Total Equity650.13M510.51M925.04M662.10M319.82M
Cash391.41M267.90M597.86M629.04M346.47M
Total Debt2.79M-61.13M55.34M-
Net Debt-388.62M-267.90M-536.72M-573.70M-

Cash Flow

Currency: TWD2021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-140.39M-189.49M-67.20M-186.01M-350.29M
Investing Cash Flow96.65M-1.65M-288.02M188.31M-
Financing Cash Flow344.17M67.05M685.17M28.89M-
Capital Expenditure3.75M2.01M12.38M10.52M3.73M
Free Cash Flow-144.14M-191.49M-79.58M-196.53M-354.02M
FCF to OCF102.67%101.06%118.42%105.65%101.07%

Key Statistics & Ratios

Market Cap7.89B
Enterprise Value6.97B
Trailing P/E0.00
Forward P/E0.00
Price / Sales8225.42
Price / Book17.62
EPS-4.20
Book Value4.15
Revenue (TTM)959.00K
Gross Profit (TTM)579.00K
EBITDA-360.74M
Profit Margin0.00%
Operating Margin-38257.97%
Return on Equity-87.38%
Return on Assets-33.77%
Shares Outstanding101.13M
Shares Float56.80M
Beta-0.30
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%